Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 28, 2014
Pharmacy Choice - News - Front Page Healthcare News - July 28, 2014

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/28/14 - 22nd Century Group Engages CRO for FDA Regulatory Activities of Company's Modified Risk Cigarettes
By a News Reporter-Staff News Editor at Pharma Business Week 22nd Century Group, Inc. announced that it has engaged a major a contract research organization with extensive experience in tobacco exposure studies to assist the Company in certain regulatory activities at the Center for Tobacco Products of the U.S. Food and Drug Administration relate
7/28/14 - Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan
By a News Reporter-Staff News Editor at Pharma Business Week Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded...
7/28/14 - Aetna and Geisinger Health System Reach New Agreement
Aetna and Geisinger Health System today announced that they have signed a five-year contract that provides Aetna members with in-network access to all Geisinger facilities in Pennsylvania. Under the agreement, Geisinger also renewed its existing contract with Coventry, which was acquired by Aetna in 2013. Members of all Aetna and Coventry commercia
7/28/14 - AG Gansler: Astellas Pharma US Inc. Pays $7.3 Million to Resolve False Claims Act Allegations Related to Marketing of Antifungal Agent Company promoted Mycamine to treat children without FDA approval
Baltimore, MD Attorney General Douglas F. Gansler announced today that Maryland, joined by multiple states and the federal government, has settled allegations that Astellas Pharma US, Inc. caused false claims to be submitted to federal and state health care programs in connection with its marketing and promotion of the drug Mycamine for pediatric
7/28/14 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Animal Generic Drug User Fee Cover Sheet
SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled "Animal Generic Drug User Fee Cover Sheet" has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995.. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Col
7/28/14 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Medical Devices; Reports of Corrections and...
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Medical Devices; Reports of Corrections and Removals. SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled "Medical Devices; Reports of Corrections and Removals" has been approved by the Office of Manageme
7/28/14 - Anthera Pharmaceuticals Announces Acquisition of Sollpura liprotamase for Exocrine Pancreatic Insufficiency From Eli Lilly and Company
By a News Reporter-Staff News Editor at Clinical Trials Week Anthera Pharmaceuticals, Inc. announced that it has acquired Sollpura, a novel investigational Pancreatic Enzyme Replacement Therapy from Eli Lilly and Company. EPI is estimated to afflict more than 150,000 patients in the United States alone, with more than US $600 million spent on enz
7/28/14 - Aqua Pharmaceuticals, LLC Announces the U.S. Food and Drug Administration (FDA) Approval of ACTICLATE? (doxycycline hyclate USP) Tablets, 150 mg and 75 mg
West Chester- based Aqua Pharmaceuticals, an Almirall company, today announces the U.S. Food and Drug Administration approval of the NDA for ACTICLATE? Tablets, 150 mg and 75 mg, thereby continuing Aqua s leadership in medical dermatology and oral antibiotics for acne. We are pleased to bring ACTICLATE? to market, said Craig Ballaron,
7/28/14 - Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office
By a News Reporter-Staff News Editor at Clinical Trials Week Arena Pharmaceuticals, Inc. announced that it was granted U.S. Patent applications for APD371 have been filed in 23 jurisdictions, including the United States, Europe, Japan and China. Keywords for this news article include: Arena Pharmaceuticals, Arena Pharmaceuticals Inc., Government
7/28/14 - Batu Biologics Strategy for FDA Approval of Lung Cancer Immunotherapy Featured in San Diego Business Journal
The article, which was published in the July 21 st edition, discussed the company s strategy in developing its immunotherapeutic lung cancer vaccine, ValloVax, for which FDA Investigational New Drug submission is planned in Q1 of 2015.. Alan Lewis and Thomas Ichim, subsequent to the $26 million purchase of Medistem by the NYSE- traded company In
7/28/14 - BHH Unveils Outpatient Wound Healing Program [Manufacturing Close - Up]
Bakersfield Heart Hospital opened their outpatient wound healing program to address the growing need for wound care and help patients overcome issues related to various types of wounds. According to a media release, Bakersfield Heart Hospital's Center for Wound Healing is located directly across the street from the hospital at 3012 Sillect Avenue.
7/28/14 - BioAlliance Pharma and Topotarget Confirm Cross-border Merger [Professional Services Close - Up]
BioAlliance Pharma SA and Topotarget A/S have completed the cross- border merger between the two companies to create Onxeo, dedicated to orphan oncology diseases. According to a media release, BioAlliance Pharma, as the absorbing entity, will remain admitted to trading on Euronext Paris and will file for approval on the secondary trading and offici
7/28/14 - BioAlliance Pharma and Topotarget: Cross-Border Merger Now legally Effective [Manufacturing Close - Up]
BioAlliance Pharma SA and Topotarget reported that the cross- border merger between the two companies is legally effective as of July 22 to create Onxeo, dedicated to orphan oncology diseases. In its release on July 23, BioAlliance Pharma, as the absorbing entity, said it will remain admitted to trading on Euronext Paris and will file for approval
7/28/14 - Boston Scientific Receives CE Mark For The New 25 mm Lotus? Valve System
By a News Reporter-Staff News Editor at Biotech Business Week Boston Scientific Corporation has received CE Mark and begun the European commercial launch of its new 25 mm Lotus? Transcatheter Aortic Valve Implantation System, complementing the currently available 23 mm and 27 mm valve sizes. Nicolas Van Mieghem at Erasmus Medical Center, Rotter
7/28/14 - Bryant: Obama to blame for drop in state's insured [Northeast Mississippi Daily Journal, Tupelo :: ]
Phil Bryant placed the blame squarely on President Barack Obama's Affordable Care Act for Mississippi's status as the only state where the number of people without health insurance has increased. "If statistics show that the ill-conceived and so-called Affordable Care Act is resulting in higher rates of uninsured people in Mississippi, I'd say tha
7/28/14 - CANbridge Life Sciences And EUSA Pharma Form Agreement to Commercialize Caphosol in China
CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has entered into an exclusive partnership with EUSA Pharma, a Jazz Pharmaceuticals company, to commercialize Caphosol in China. Caphosol represents the second oncology product we will commercialize in China and will meet
7/28/14 - CANbridge Life Sciences And EUSA Pharma Form Agreement to Commericalize Caphosol in China
CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has entered into an exclusive partnership with EUSA Pharma, a Jazz Pharmaceuticals company, to commercialize Caphosol in China. Caphosol represents the second oncology product we will commercialize in China and will meet
7/28/14 - Cerus Submits Final Module in Premarket Approval PMA Application Process for INTERCEPT Platelets
By a News Reporter-Staff News Editor at Biotech Business Week Cerus Corporation announced today that it has submitted the third and final module for its Premarket Approval application to the U.S. Food and Drug Administration, for review of the INTERCEPT Blood System for platelets. The INTERCEPT platelet submission was completed at the end of the
7/28/14 - Changes in generic pill color and shape disrupt use
By a News Reporter-Staff News Editor at Cardiovascular Week Boston, MA- Generic versions of the same prescription drug are clinically interchangeable but often look different depending on the manufacturer. Studying a national cohort of patients who recently suffered a heart attack, researchers from Brigham and Women's Hospital have found that var
7/28/14 - Cytonics Gets FDA Approval of New Drug Application [Manufacturing Close - Up]
Cytonics Corp. has reported that an Investigational New Drug application for a phase I/II clinical trial of the company's APIC Cell-Free System has been approved by the FDA. According to a release from the company, the system is indicated for the rapid preparation of concentrated protease inhibitors in plasma, specifically Alpha-2-Macroglobulin, fo
7/28/14 - Data on Large B-Cell Lymphoma Detailed by F.D. Xavier and Co-Authors (Time-to-treatment of diffuse large B-cell lymphoma in Sao Paulo)
According to news reporting out of Sao Paulo, Brazil, by NewsRx editors, research stated, "Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, accounting for nearly 50% of the cases in the Hematology Department of the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo and Instituto do Cancer do Es
7/28/14 - FDA Approves the Freedom Portable Driver That Powers The SynCardia Total Artificial Heart
By a News Reporter-Staff News Editor at Pharma Business Week The Freedom portable driver received FDA approval on June 26, 2014 for use with the SynCardia temporary Total Artificial Heart as a bridge to transplantation in cardiac transplant candidates who are clinically stable. "With the FDA approval letter for the Freedom portable driver, Sy
7/28/14 - FDA Designates Opioid Overdose Treatment for Fast Track Development Program
The Fast Track program of the FDA is designed to expedite the development and review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. AntiOp and the FDA may also be able to employ additional tools to expedite the FDA review process such as "rolling subm
7/28/14 - FDA Grants Genentech's Avastin Priority Review for Certain Types of Cervical Cancer
By a News Reporter-Staff News Editor at Pharma Business Week Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin plus chemotherapy for the treatment of women with persistent, recurrent or metast
7/28/14 - FDA Grants Special Protocol Assessment SPA Agreement for Starpharma Phase 3 Recurrent BV Trial
By a News Reporter-Staff News Editor at AIDS Weekly Starpharma Holdings Ltd announced that the US Food and Drug Administration has granted Special Protocol Assessment agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel bacterial vaginosis product for the prevention of recurrent BV. Starpharma will now co
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
West Virginia Best Practice Prescribing & Drug Diversion Training
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415